The good, the bad and the ugly incidents that fetishised the ‘Ember’ months, notwithstanding, the year 2024 rolled off Earth’s cliff two days ago, plunging into the domain of history.
CBP-501 is under clinical development by CanBas and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 72% phase transition success rate (PTSR) ...